Who are the top shareholders of the Suraksha Diagno.?

The top shareholders of Suraksha Diagno include Ritu Mittal with 15.89%, Orbimed Asia II Mauritius Limited at 12.88%, mutual funds with 19.26%, foreign institutional investors holding 14.46%, and individual investors at 13.52%.

The top shareholders of Suraksha Diagno include the promoters, who hold the majority of shares. The promoter with the highest holding is Ritu Mittal, owning 15.89%. Additionally, Orbimed Asia II Mauritius Limited is the highest public shareholder with a stake of 12.88%. Mutual funds collectively hold 19.26% through 8 schemes, while foreign institutional investors (FIIs) hold 14.46% across 10 entities. Individual investors account for 13.52% of the shareholding.

Has Suraksha Diagno. declared dividend?

No Dividend History Available

Is Suraksha Diagno. technically bullish or bearish?

As of June 23, 2025, the market for Suraksha Diagno is in a neutral stance with no clear direction, as indicated by mixed signals from key technical indicators like MACD, RSI, and moving averages.

As of 23 June 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, reflecting a lack of clear direction. The MACD shows no signal on both the weekly and monthly time frames, while the RSI also indicates no signal on the weekly and monthly. The Bollinger Bands are mildly bullish on the weekly but do not provide strong confirmation. Moving averages, KST, Dow Theory, and OBV show no trends, further supporting the neutral stance. Overall, the indicators suggest indecision in the market for Suraksha Diagno.

Who are the peers of the Suraksha Diagno.?

Suraksha Diagno.'s peers include Thyrocare Tech., Krsnaa Diagnost., Laxmi Dental, Vimta Labs, Tarsons Products, 3B Blackbio, Sastasundar Ven., Prevest Denpro, and One Global Serv. The company has average management risk and good growth, with its 1-year return data unavailable for comparison.

Peers: The peers of Suraksha Diagno. are Thyrocare Tech., Krsnaa Diagnost., Laxmi Dental, Vimta Labs, Tarsons Products, 3B Blackbio, Sastasundar Ven., Prevest Denpro, and One Global Serv.<BR><BR>Quality Snapshot: Excellent management risk is observed at Laxmi Dental and One Global Serv, while Average management risk is found at Krsnaa Diagnost., Vimta Labs, Suraksha Diagno., 3B Blackbio, and Prevest Denpro, and the rest. Good growth is noted at Laxmi Dental, Suraksha Diagno., 3B Blackbio, and One Global Serv, while Average growth is seen at Sastasundar Ven., and the rest. Excellent capital structure is present at Thyrocare Tech., Krsnaa Diagnost., Vimta Labs, 3B Blackbio, Sastasundar Ven., and Prevest Denpro, while Good capital structure is found at Laxmi Dental and Suraksha Diagno., and the rest.<BR><BR>Return Snapshot: Thyrocare Tech. has the highest 1-year return at 85.70%, while Tarsons Products has the lowest at -23.12%. Suraksha Diagno.'s 1-year return is not available for comparison. Additionally, the peers with negative six-month returns include Tarsons Products, 3B Blackbio, One Global Serv, and Nureca.

What does Suraksha Diagno. do?

Suraksha Diagnostic Ltd is a small-cap healthcare services company, incorporated in 2005, with net sales of 651 Cr and a net profit of 74 Cr as of March 2025. Key metrics include a P/E ratio of 51.00 and a market cap of INR 1,650 Cr.

Overview: <BR>Suraksha Diagnostic Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated in 2005 as Suraksha Diagnostic Private Limited and later converted to a public limited company. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 651 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 74 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 1,650 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 51.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.24 <BR>Return on Equity: 18.49% <BR>Price to Book: 9.19 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Suraksha Diagno.?

As of 24th July, Suraksha Diagnostic Ltd has a market capitalization of 1,597.00 Cr, with Net Sales of 252.08 Cr and a Net Profit of 31.82 Cr reported in the latest four quarters. The company has Shareholder's Funds of 179.41 Cr and Total Assets of 300.20 Cr as of March 2024.

As of 24th July, Suraksha Diagnostic Ltd has a market capitalization of 1,597.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, Suraksha Diagnostic Ltd reported Net Sales of 252.08 Cr and a Net Profit of 31.82 Cr.<BR><BR>As of March 2024, the company has Shareholder's Funds amounting to 179.41 Cr and Total Assets of 300.20 Cr.

When is the next results date for Suraksha Diagno.?

Suraksha Diagno. will declare its results on 08 August 2025.

Suraksha Diagno. will declare its results on 08 August 2025.

How has been the historical performance of Suraksha Diagno.?

Suraksha Diagno has shown positive financial growth over the past two years, with net sales increasing to 252.09 Cr in March 2025 from 218.71 Cr in March 2024, and profit after tax rising to 30.98 Cr from 23.13 Cr, reflecting improved profitability and a stable financial position.

Answer:<BR>The historical performance of Suraksha Diagno shows a positive trend in key financial metrics over the past two years.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Suraksha Diagno reported net sales of 252.09 Cr, an increase from 218.71 Cr in March 2024. The total operating income mirrored this growth, reaching 252.09 Cr, while total expenditure (excluding depreciation) rose to 170.85 Cr from 148.64 Cr. Operating profit, excluding other income, improved to 81.24 Cr from 70.07 Cr, leading to an operating profit margin of 32.23%, slightly up from 32.04%. Profit before tax also saw a significant increase to 41.41 Cr from 31.45 Cr, resulting in a profit after tax of 30.98 Cr, compared to 23.13 Cr the previous year. This reflects a PAT margin increase to 12.29% from 10.58%. The company's total assets grew to 333.52 Cr from 300.20 Cr, while total liabilities increased to 333.52 Cr from 300.20 Cr, indicating a stable financial position. Cash flow from operating activities improved to 63.00 Cr from 60.00 Cr, contributing to a consistent closing cash balance of 2.00 Cr over the last two years. Overall, Suraksha Diagno has demonstrated solid growth in revenue and profitability, alongside a stable asset and liability structure.

Is Suraksha Diagno. overvalued or undervalued?

As of October 14, 2025, Suraksha Diagnostics is considered overvalued with a PE ratio of 45.39, a Price to Book Value of 7.08, and an EV to EBITDA of 18.26, all significantly above industry norms, while its stock has underperformed the Sensex with a year-to-date return of -22.4%.

As of 14 October 2025, the valuation grade for Suraksha Diagnostics has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this assessment: the PE ratio stands at 45.39, the Price to Book Value is 7.08, and the EV to EBITDA is 18.26, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Suraksha Diagnostics' PE ratio is notably lower than that of Max Healthcare, which has a PE of 93.68, and higher than Apollo Hospitals, which is valued at 70.7. The PEG ratio for Suraksha is 0.00, suggesting a lack of growth expectations compared to its price, further reinforcing the overvaluation stance. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -22.4% compared to the Sensex's 4.98%, which underscores the potential disconnect between its current valuation and market performance.

Are Suraksha Diagno. latest results good or bad?

Suraksha Diagnostic's latest results show strong revenue growth of 17.95% year-on-year, reaching ₹78.73 crores, but profitability has declined, with net profit down 13.06% and significant margin compression. Overall, while revenue growth is positive, the declining profitability raises concerns about sustainability.

Suraksha Diagnostic's latest results present a mixed picture. On one hand, the company achieved significant revenue growth, with net sales increasing by 17.95% year-on-year to ₹78.73 crores, marking the highest quarterly revenue in its history. This growth reflects strong demand for its diagnostic services and represents the seventh consecutive quarter of sequential revenue growth.<BR><BR>However, the profitability metrics are concerning. The net profit for Q2 FY26 was ₹8.99 crores, which is a decline of 13.06% year-on-year and a decrease of 4.36% compared to the previous quarter. Additionally, both operating margin and PAT margin have contracted significantly, with operating margins dropping to 30.62% from 34.74% a year ago, indicating substantial cost pressures that are impacting profitability.<BR><BR>Overall, while the revenue growth is a positive sign, the declining profitability and margin compression raise questions about the sustainability of this growth. The company faces challenges in translating its revenue gains into adequate profit, suggesting that the latest results could be viewed as more negative than positive due to the margin pressures and declining net profit.

Should I buy, sell or hold Suraksha Diagno.?

Which are the latest news on Suraksha Diagno.?

Why is Suraksha Diagno. falling/rising?

As of 03-Dec, Suraksha Diagnostic Ltd's stock price is at 279.05, down 1.1% and reflecting a significant decline of 25.71% year-to-date. Despite increased investor participation, the stock remains in a bearish trend, trading below its moving averages and facing ongoing challenges.

As of 03-Dec, Suraksha Diagnostic Ltd's stock price is falling, currently at 279.05, reflecting a decrease of 3.1 (-1.1%). The stock has been on a downward trend, having lost 5.04% over the last two days and showing a significant decline of 11.73% over the past month, while the benchmark Sensex has gained 1.34% in the same period. Year-to-date, the stock has decreased by 25.71%, contrasting sharply with the Sensex's increase of 8.92%.<BR><BR>The stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 76.37% against the 5-day average, the overall performance remains weak. This suggests that while more investors are engaging with the stock, it has not translated into positive price movement.<BR><BR>Additionally, the stock's performance today is described as inline with the sector, but the consecutive falls and overall negative returns highlight ongoing challenges. Although the company has a strong ability to service debt and healthy long-term growth indicators, these factors have not yet been sufficient to reverse the current downward trajectory of the stock price.